RT Journal Article
SR Electronic
T1 Correlation of patient serum IgG, IgA and IgM antigen binding with COVID-19 disease severity using multiplexed SARS-CoV-2 antigen microarray and maintained relative IgA and IgM antigen binding over time
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.22.22278930
DO 10.1101/2022.08.22.22278930
A1 Le Berre, Marie
A1 Paulovčáková, Terézia
A1 De Marco Verissimo, Carolina
A1 Doyle, Seán
A1 Dalton, John P.
A1 Masterson, Claire
A1 Martínez, Eduardo Ribes
A1 Walsh, Laura
A1 Gormley, Conor
A1 Laffey, John G.
A1 McNicholas, Bairbre
A1 Simpkin, Andrew J.
A1 Kilcoyne, Michelle
YR 2022
UL http://medrxiv.org/content/early/2022/08/25/2022.08.22.22278930.abstract
AB Zoonotic spillover of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to humans in December 2019 caused the coronavirus disease 2019 (COVID-19) pandemic. Serological monitoring is critical for detailed understanding of individual immune responses to infection and protection to guide clinical therapeutic and vaccine strategies. We developed a high throughput multiplexed SARS-CoV-2 antigen microarray incorporating spike (S) and nucleocapsid protein (NP) and fragments expressed in various hosts which allowed simultaneous assessment of serum IgG, IgA, and IgM responses. Antigen glycosylation influenced antibody binding, with S glycosylation generally increasing and NP glycosylation decreasing binding. Purified antibody isotypes demonstrated a binding pattern and intensity that differed from the same isotype in the presence of other isotypes in whole serum, probably due to competition. Using purified antibody isotypes from naïve Irish COVID-19 patients, we correlated antibody isotype binding to different panels of antigens with disease severity, with significance for binding to the S region S1 expressed in insect cells (S1 Sf21) for all three antibody isotypes. Assessing longitudinal response for constant concentrations of antibody isotypes for a subset of patients demonstrated that while the relative proportion of antigen-specific IgGs decreased over time for severe disease, the relative proportion of antigen-specific IgA binding remained at the same magnitude at 5 and 9 months post-first symptom onset. Further, the relative proportion of IgM binding decreased for S antigens but remained the same for NP antigens. This may support antigen specific serum IgA and IgM playing a role in maintaining longer-term protection, of importance for developing and assessing vaccine strategies. Overall, these data demonstrate the multiplexed platform as a sensitive and useful platform for expanded humoral immunity studies, allowing detailed elucidation of antibody isotypes response against multiple antigens. This approach will be useful for monoclonal antibody therapeutic studies and screening of donor polyclonal antibodies for patient infusions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMK acknowledges Science Foundation Ireland (SFI) COVID-19 Rapid Response Phase 2 Fund (grant number 20/COV/8477) for funding this study. BMcN thanks the Health Research Board for funding the National Irish COVID-19 Biobank (NICB). SD thanks SFI COVID-19 Rapid Response Phase 1 Fund (grant number 20/COV/0048).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the use of human serum samples was granted by the Galway University Hospital research ethics committee (C.A. 1928) and the National Research Ethics Committee (research permit 20-NREC-COV-20).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript and supplementary material